The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
Primary Purpose
Asthma, Bronchial Hyperresponsiveness
Status
Completed
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Beclomethasone dipropionate HFA
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Asthma focused on measuring asthma, preschool children, bronchial hyperresponsiveness, beclometasone dipropionate - HFA, Qvar, Adenosine Challenge test
Eligibility Criteria
Inclusion Criteria:
- clinical diagnosis of mild asthma
- children aged between 3 - 6 years old
- able to perform spirometry and adenosine challenge test
- positive challenge test at the time of inclusion
- without prophylactic treatment for asthma
- signed informed consent to join the research by the parents or legal tutor
Exclusion Criteria:
- other chronic diseases
- use of oral steroids in the last two months
- emergency room visit in the last two months
- pneumonia in the last two months
- impossibility to perform lung function tests
- disagreement of the parents or legal tutor
Sites / Locations
- Rambam Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
placebo, adenosine challenge test
Qvar, adenosine challenge test
Arm Description
Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
Outcomes
Primary Outcome Measures
Adenosine Challenge Test
Adenosine challenge test were measured and described as PC 20 - the concentration that corresponded to a FEV1 impairment equal or bigger than 20%. The stage was also recorded
Secondary Outcome Measures
Full Information
NCT ID
NCT01006655
First Posted
November 2, 2009
Last Updated
October 28, 2015
Sponsor
Rambam Health Care Campus
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01006655
Brief Title
The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
Official Title
The Effect of HFA - Beclomethasone Dipropionate - Qvar - on Bronchial Hyperreactivity in Preschool Children
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rambam Health Care Campus
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Respiratory diseases including Asthma are high prevalent among preschool children. Specific treatment, nowadays, include steroid inhalers and anti leukotrienes. It is known that the amount of the drug reaching small airways and lungs is bigger how much smaller the particles liberated by inhalers. Beclometasone is being used for treating asthma for 30 years. Lately emerged a new presentation of beclometasone, which liberates particles as small as 2.1 µg, that is supposed to reach the small airways at higher concentrations and be more suitable to patients who don't cooperate properly to the procedure of inhalation.
The investigators' group has reported successfully the possibility to perform Pulmonary Challenge tests (adenosine, methacholine and exercise) in tender age. Other studies reported relation between asthma control and reduction in airway hyperreactivity. The purpose of this study is to evaluate the efficacy of Beclometasone dipropionate - Qvar to reduce airways hyperreactivity in preschool children, as demonstrated by adenosine challenge test.
Detailed Description
26 - 30 patients, between 3 -6 years old, mild asthmatics, with positive adenosine challenge test, will received in a randomized, double blind, cross over assignment Beclometasone dipropionate (100µg twice a day) or placebo, through an inhaler (autohaler) device, attached to a spacer device, during four consecutive weeks. Adenosine Challenge test will be performed another time at the end of this four weeks period. After 2 weeks with no medication (wash out period) the patients will receive the second intervention (beclometasone dipropionate or placebo) in a cross over manner and will be submitted to the last adenosine challenge test.
Clinical evaluation, resting spirometry and subjective evaluation through an analogical symptoms scale will be recorded in each visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Bronchial Hyperresponsiveness
Keywords
asthma, preschool children, bronchial hyperresponsiveness, beclometasone dipropionate - HFA, Qvar, Adenosine Challenge test
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo, adenosine challenge test
Arm Type
Placebo Comparator
Arm Description
Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
Arm Title
Qvar, adenosine challenge test
Arm Type
Active Comparator
Arm Description
Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
Intervention Type
Drug
Intervention Name(s)
Beclomethasone dipropionate HFA
Other Intervention Name(s)
Qvar
Intervention Description
100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
inhalation twice a day for one month, preceded and followed by adenosine challenge test
Primary Outcome Measure Information:
Title
Adenosine Challenge Test
Description
Adenosine challenge test were measured and described as PC 20 - the concentration that corresponded to a FEV1 impairment equal or bigger than 20%. The stage was also recorded
Time Frame
ten weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
clinical diagnosis of mild asthma
children aged between 3 - 6 years old
able to perform spirometry and adenosine challenge test
positive challenge test at the time of inclusion
without prophylactic treatment for asthma
signed informed consent to join the research by the parents or legal tutor
Exclusion Criteria:
other chronic diseases
use of oral steroids in the last two months
emergency room visit in the last two months
pneumonia in the last two months
impossibility to perform lung function tests
disagreement of the parents or legal tutor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lea Bentur, MD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Medical Center
City
Haifa
Country
Israel
12. IPD Sharing Statement
Citations:
PubMed Identifier
17508971
Citation
Menzies D, Nair A, Hopkinson P, McFarlane L, Lipworth BJ. Differential anti-inflammatory effects of large and small particle size inhaled corticosteroids in asthma. Allergy. 2007 Jun;62(6):661-7. doi: 10.1111/j.1398-9995.2007.01376.x.
Results Reference
background
PubMed Identifier
12153967
Citation
Koh YY, Lee MH, Sun YH, Park Y, Kim CK. Improvement in bronchial hyperresponsiveness with inhaled corticosteroids in children with asthma: importance of family history of bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2002 Aug 1;166(3):340-5. doi: 10.1164/rccm.2101158.
Results Reference
background
PubMed Identifier
17218573
Citation
Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest. 2007 Jan;131(1):180-6. doi: 10.1378/chest.06-1402.
Results Reference
background
Learn more about this trial
The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
We'll reach out to this number within 24 hrs